Gestrinona, lipedema e os limites da extrapolação teórica na prática clínica: uma revisão narrativa crítica
Gestrinone, lipedema, and the limits of theoretical extrapolation in clinical practice: a critical narrative review
Marcelo Fernandes Lima
Resumo
Palavras-chave
Abstract
Lipedema is a chronic inflammatory disorder of adipose tissue that predominantly affects women and is characterized by disproportionate subcutaneous fat accumulation, pain, spontaneous bruising, and significantly impaired quality of life. Although hormonal influences on its pathophysiology have been increasingly recognized, evidence-based treatment options remain limited. Recently, gestrinone has been proposed as an off-label therapy based on hormonal mechanistic hypotheses. A critical narrative review of the literature was conducted using international databases to identify clinical or pharmacological evidence supporting its use in lipedema. No clinical trials, observational studies, case series, or case reports directly evaluating this therapy were identified. Existing proposals rely exclusively on theoretical extrapolations lacking clinical validation. Therefore, current evidence does not support the use of gestrinone in the treatment of lipedema, and its use should be considered experimental until adequately designed clinical studies are available.
Keywords
References
1 Wold LE, Hines EA Jr, Allen EV. Lipedema of the legs. Ann Intern Med. 1951;34(5):1243-50.
2 Herbst KL, Kahn LA, Iker E, et al. Standard of care for lipedema in the United States. Phlebology. 2021;36(10):779-96.
3 Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin. 2012;33(2):155-72.
4 Buck DW 2nd, Herbst KL. Lipedema: a relatively common disease with extremely common misconceptions. Plast Reconstr Surg Glob Open. 2016;4(9):e1043.
5 Katzer K, Hill JL, McIver KB, Foster MT. Lipedema and the potential role of estrogen in excessive adipose tissue accumulation. Int J Mol Sci. 2021;22(21):11720.
6 Torre YS, Wadeea R, Rosas V, Herbst KL. Lipedema: friend and foe. Horm Mol Biol Clin Investig. 2018;33(1):20170076.
7 Felmerer G, Stylianaki A, Hollmén M, et al. Increased levels of VEGF-C and macrophage infiltration in lipedema patients without changes in lymphatic vascular morphology. Sci Rep. 2020;10(1):10947.
8 Child AH, Gordon KD, Sharpe P, et al. Lipedema: an inherited condition. Am J Med Genet A. 2010;152A(4):970-6.
9 Coutinho EM. Treatment of endometriosis with gestrinone (R-2323), a synthetic antiestrogen, antiprogesterone. Am J Obstet Gynecol. 1982;144(8):895-8.
10 Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol. 1997;176(2):387-94.
11 Vercellini P, Crosignani PG, Somigliana E, Berlanda N, Barbara G, Fedele L. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod. 2009;24(10):2504-14.
12 Kruppa P, Georgiou I, Biermann N, Prantl L, Klein-Weigel P, Ghods M. Lipedema: pathogenesis, diagnosis, and treatment options. Dtsch Arztebl Int. 2020;117(22-23):396-403.
13 Amato AC, Amato JS, Benitti D. Lack of scientific evidence for the use of gestrinone in the treatment of lipedema: a systematic review. Cureus. 2025;17(11):e97213.
14 Viana DPC, Câmara LC. Hormonal links between lipedema and gynecological disorders: therapeutic roles of gestrinone and drospirenone. J Adv Med Med Res. 2025;37(2):175-88.
15 O’Brien SN, Welter BH, Mantzke KA, Price TM. Identification of progesterone receptor in human subcutaneous adipose tissue. J Clin Endocrinol Metab. 1998;83(2):509-13.
Submitted date:
01/27/2026
Accepted date:
04/03/2026
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email